Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

Rodríguez, Natalia; Martin, Marta; 2EPs Group

doi:http://dx.doi.org/10.1038/s41537-022-00215-1

Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

License

Citation

Rodríguez N, Gassó P, Martínez-Pinteño A, Segura ÀG, Mezquida G, Moreno-Izco L, et al. Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients. Schizophrenia (Heidelb). 2022 Apr 27;8(1):45. DOI: 10.1038/s41537-022-00215-1

Abstract

A better understanding of schizophrenia subtypes is necessary to stratify the patients according to clinical attributes. To explore the genomic architecture of schizophrenia symptomatology, we analyzed blood co-expression modules and their association with clinical data from patients in remission after a first episode of schizophrenia. In total, 91 participants of the 2EPS project were included. Gene expression was assessed using the Clariom S Human Array. Weighted-gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its correlation with global functioning, clinical symptomatology, and premorbid adjustment. Among the 25 modules identified, six modules were significantly correlated with clinical data. These modules could be clustered in two groups according to their correlation with clinical data. Hub genes in each group showing overlap with risk genes for schizophrenia were enriched in biological processes related to metabolic processes, regulation of gene expression, cellular localization and protein transport, immune processes, and neurotrophin pathways. Our results indicate that modules with significant associations with clinical data showed overlap with gene sets previously identified in differential gene-expression analysis in brain, indicating that peripheral tissues could reveal pathogenic mechanisms. Hub genes involved in these modules revealed multiple signaling pathways previously related to schizophrenia, which may represent the complex interplay in the pathological mechanisms behind the disease. These genes could represent potential targets for the development of peripheral biomarkers underlying illness traits in clinical remission stages after a first episode of schizophrenia.